Document Detail

Immunoreactivity of antibodies raised against synthetic peptide fragments predicted from mid portions of dystrophin cDNA.
MedLine Citation:
PMID:  2205709     Owner:  NLM     Status:  MEDLINE    
We synthesized 3 peptide fragments predicted by residues 2354-2368 (peptide I), 2310-2324 (peptide II) and 2255-2269 (peptide III) on the mid-portion of the human dystrophin cDNA map where the most frequent intragenic deletions occurred in Duchenne muscular dystrophy. Rabbit antibodies against these peptides were raised and cryosections of 47 biopsied muscles were studied immunohistochemically. The 47 biopsied muscles included the quadriceps femoris muscles of 8 Duchenne muscular dystrophy patients, 8 child and 5 adult normal controls, 1 facioscapulohumeral dystrophy, 2 limb girdle dystrophy, 3 myotonic dystrophy, 3 polymyositis, 1 mitochondrial myopathy, 1 nemaline myopathy, 3 amyotrophic lateral sclerosis and the extensor digitorum longus muscles of 6 mdx mice (C57BL/10ScSn-mdx) and 6 normal control mice (C57BL/10ScSn). The peptide I antiserum continuously stained the myofiber surface membranes in 8 child and 5 adult normal control muscles, and in 14 other muscles from various neuromuscular diseases, but failed to stain the surface membranes in normal control mice. The surface membranes of 8 Duchenne muscles were not stained by the peptide I antiserum except for a few myofibers. Although the ELISA titers of peptide I, II and III antibodies were high, immunostaining by peptide II antiserum showed no reaction in the myofibers of any of the biopsied muscles, and immunostaining by peptide III antiserum revealed faint reactions on the myofiber surface membranes of all biopsied muscles, including the mdx control mouse muscles except for the Duchenne and mdx myofibers.
Y Wakayama; T Jimi; A Takeda; N Misugi; T Kumagai; S Miyake; S Shibuya
Related Documents :
10066119 - The effects of myotonic dystrophy and duchenne muscular dystrophy on the orofacial musc...
2985299 - Phosphatidic acid phosphatase activity in subcellular fractions of normal and dystrophi...
10601809 - Proximal myotonic myopathy: clinical, electrophysiological and pathological findings in...
8263549 - Dystrophin abnormalities in duchenne and becker dystrophy carriers: correlation with cy...
15169969 - Altered activity of signaling pathways in diaphragm and tibialis anterior muscle of dys...
6628609 - Effects of ph on membrane resistance in normal and dystrophic mouse skeletal muscle fib...
20428499 - Reconstruction and dissection of the entire human visual pathway using diffusion tensor...
3527139 - Analysis of fibronectin expression during human muscle differentiation.
10505439 - Indirect effect of sciatic nerve injury on the epidermal thickness of plantar glabrous ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the neurological sciences     Volume:  97     ISSN:  0022-510X     ISO Abbreviation:  J. Neurol. Sci.     Publication Date:  1990 Jul 
Date Detail:
Created Date:  1990-10-24     Completed Date:  1990-10-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375403     Medline TA:  J Neurol Sci     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  241-50     Citation Subset:  IM    
Department of Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amino Acid Sequence
Antibodies / immunology*
Base Sequence
Blotting, Western
DNA / immunology*
Mice, Inbred C57BL
Molecular Sequence Data
Muscle Proteins / genetics*
Muscles / ultrastructure
Muscular Diseases / genetics
Muscular Dystrophies / metabolism
Peptide Fragments / immunology*
Reg. No./Substance:
0/Antibodies; 0/Dystrophin; 0/Muscle Proteins; 0/Peptide Fragments; 9007-49-2/DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Complement mediated serum cytotoxicity against oligodendrocytes: a comparison with other cells of th...
Next Document:  The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease.